Abstract
Objectives The Filtered Far-UVC (FFUV) handheld disinfection device is a small portable device that emits far UVC at 222nm. The objective of this study was to evaluate the device’s ability to kill microbial bioburden on hospital surfaces and compare it to manual cleaning using germicidal sodium hypochlorite wipes.
Methods A total of 344 surfaces (86 observations per group) were sampled with 2 pairs of samples per surface- a pre- and a post-sodium hypochlorite sample, and a pre- and a post-FFUV sample. The results were analyzed via a Bayesian multilevel model that account for the correlation between sample pairs and within surfaces. Additionally, the bacterial flora recovered was identified.
Results The estimated mean colony counts for the sodium hypochlorite control and treatment groups were 20.5 (11.7 – 36.0) and 0.1 (0.0 – 0.2) colony forming units (CFUs) respectively. The FFUV control and treatment groups had mean colony counts of 22.2 (12.5 – 40.1) and 4.1 (2.3 – 7.2) CFUs. The sodium hypochlorite samples had an estimated 99.4% (99.0% – 99.7%) reduction in colony counts, while those from the FFUV group an estimated 81.4% (76.2% - 85.7%) reduction.
Conclusions The findings from this study suggest the FFUV handheld device effectively reduced microbial bioburden on real-world hospital surfaces; however, a manual clean using sodium hypochlorite was more effective in reducing bioburden. Several healthcare-associated infections (HAIs) causing pathogens (gram positive and negative bacteria) were retrieved from the surfaces indicating a potential for onward transmission.
Competing Interest Statement
The funding support for the study was received from the Freestyle Partners, LLC, and its affiliate, FSP Innovations, LLC.
Funding Statement
This manuscript is the result of work supported with resources and the use of facilities at the Central Texas Veterans Health Care System, Temple, TX. The device and funding to conduct the study was provided by Freestyle Partners, LLC, and its affiliate, FSP Innovations, LLC to PC. The study sponsor did not have a role in the study design, data collection, data analysis, data interpretation, or writing of this manuscript. The corresponding author has full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
